Pregabalin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Partial Seizures
Conditions
Partial Seizures
Trial Timeline
Mar 1, 2007 → Aug 1, 2009
NCT ID
NCT00407797About Pregabalin
Pregabalin is a approved stage product being developed by Pfizer for Partial Seizures. The current trial status is terminated. This product is registered under clinical trial identifier NCT00407797. Target conditions include Partial Seizures.
What happened to similar drugs?
17 of 20 similar drugs in Partial Seizures were approved
Approved (17) Terminated (4) Active (3)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01773993 | Pre-clinical | Completed |
| NCT01603394 | Approved | Terminated |
| NCT01463306 | Phase 3 | Completed |
| NCT01298466 | Approved | Withdrawn |
| NCT01474772 | Phase 3 | Completed |
| NCT01397006 | Approved | Withdrawn |
| NCT01020526 | Approved | Completed |
| NCT01202227 | Phase 3 | Completed |
| NCT01226667 | Approved | Completed |
| NCT00819988 | Phase 3 | Completed |
| NCT00596466 | Phase 3 | Completed |
| NCT00553280 | Phase 3 | Completed |
| NCT01061697 | Approved | Completed |
| NCT00891397 | Pre-clinical | Terminated |
| NCT00448916 | Phase 3 | Completed |
| NCT00407797 | Approved | Terminated |
| NCT00424372 | Phase 3 | Completed |
| NCT00407511 | Approved | Completed |
| NCT00346034 | Phase 3 | Completed |
| NCT00843284 | Pre-clinical | Completed |
Competing Products
20 competing products in Partial Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2007 | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| perampanel + perampanel | Eisai | Phase 1 | 29 |
| perampanel + perampanel + perampanel + Placebo | Eisai | Phase 3 | 40 |
| Perampanel + Placebo | Eisai | Approved | 35 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 29 |
| perampanel | Eisai | Phase 2 | 35 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| zonisamide | Eisai | Pre-clinical | 26 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 40 |
| Perampanel + Placebo | Eisai | Phase 3 | 40 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 40 |
| Adjunctive Zonisamide + Replacement with Zonisamide | Eisai | Approved | 43 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Rufinamide | Eisai | Phase 3 | 32 |
| Zonisamide | Eisai | Phase 3 | 40 |
| Eslicarbazepine Acetate tablets | Eisai | Pre-clinical | 26 |